How to deprescribe a PPI: a practical guide for GP pharmacists

Long-term proton pump inhibitors (PPIs) are one of the most reviewable items on any repeat list: hugely effective when needed, but frequently continued long after the original reason has gone. Knowing how to deprescribe a PPI safely — omeprazole, lansoprazole, esomeprazole and the rest — is a bread-and-butter skill in the structured medication review. This guide covers who is suitable, who should stay on treatment, and how to step down without triggering rebound symptoms.

This is general guidance to support review. Always individualise the decision and follow your local formulary and guidance for the specific patient.

Why review long-term PPIs

PPIs are often started for a defined reason — a course for dyspepsia, gastroprotection during a short NSAID course, treatment of reflux — and then continued indefinitely by repeat prescribing. Reviewing them reduces unnecessary long-term medicine, cost and the small risks associated with prolonged use, while making sure the people who genuinely need ongoing acid suppression keep it. The goal is the right patients on the right treatment, which is exactly what deprescribing means.

Who should NOT be deprescribed

Before considering a reduction, screen out the patients for whom a PPI is doing important work. Long-term continuation is generally appropriate for Barrett's oesophagus, severe or complicated erosive oesophagitis, a documented bleeding ulcer, Zollinger-Ellison syndrome, and for gastroprotection where the risk factor persists — for example someone who remains on an NSAID or has ongoing high GI-bleed risk on antiplatelet therapy. Any alarm or red-flag symptom (unexplained weight loss, dysphagia, GI bleeding, persistent vomiting, iron-deficiency anaemia) needs assessment, not a quiet dose reduction.

Deciding suitability

For everyone else, the question is whether the original indication still applies and whether symptoms are controlled. A patient who has been symptom-free on a full-dose PPI for the original problem, with no ongoing gastroprotection need, is a reasonable candidate for a trial of stepping down. Shared decision-making matters here: explain why you are reviewing it, what the plan is, and that it can be reversed if symptoms return.

Step down, don't just stop

Stopping a full-dose PPI abruptly can cause rebound acid hypersecretion — a temporary surge in acid production that produces heartburn and can be mistaken for the original condition returning. Two common approaches are to halve the dose (or move to a lower-strength or on-demand regimen) for a few weeks before stopping, or to step to the lowest effective dose and then to as-needed use. Choosing the gentler route makes the difference between a successful stop and a patient restarting because the rebound felt like relapse.

Managing rebound and symptom return

Warn the patient that a few weeks of increased heartburn can happen and does not necessarily mean they need the PPI back. Offer an as-needed antacid or alginate to cover the transition, and reinforce lifestyle measures where relevant. Agree what to do if symptoms persist beyond the expected window: reassess rather than automatically reinstating full-dose treatment for life. If symptoms are genuinely uncontrolled at the lowest step, settling on the lowest effective maintenance dose is a perfectly good outcome.

Documenting and coding the review

Record the indication you reviewed, the decision and its rationale, the counselling given (including the rebound warning and safety-net), and the follow-up plan. Clear coding lets the next clinician see this was a considered review, not an oversight — the same discipline covered in clinical coding for GP pharmacists. Good documentation is what turns a deprescribing conversation into a safe, auditable action.

How Medicine in Practice helps: our deprescribing and medication-review training gives you the frameworks and realistic cases to make PPI reviews confident and safe, including the patient conversation.

Frequently asked questions

Can you stop omeprazole abruptly?

Stopping a full-dose PPI such as omeprazole suddenly can cause rebound acid hypersecretion, a temporary increase in stomach acid that produces heartburn and can feel like the original problem returning. Stepping the dose down before stopping, or moving to as-needed use, reduces this.

What is PPI rebound acid hypersecretion?

It is a temporary surge in acid production after stopping or reducing a PPI, causing heartburn or reflux symptoms for a few weeks. It can be mistaken for relapse and lead to unnecessary restarting, which is why gradual step-down and a clear warning to the patient help.

Which patients should stay on a long-term PPI?

Patients with Barrett's oesophagus, severe or complicated erosive oesophagitis, a history of bleeding ulcer, Zollinger-Ellison syndrome, or an ongoing need for gastroprotection (for example continued NSAID or high-GI-risk antiplatelet use) generally continue long term. Any red-flag symptom needs assessment, not deprescribing.

How do you step down a PPI?

Common approaches are to halve the dose or move to a lower strength for a few weeks before stopping, or to reduce to the lowest effective dose and then use it on demand. Pair the change with an as-needed antacid or alginate and a clear safety-net.

What if reflux symptoms come back after stopping?

Explain that some rebound heartburn is expected and does not automatically mean lifelong treatment is needed. Cover the transition with an as-needed antacid, reassess if symptoms persist beyond the expected window, and settle on the lowest effective dose if ongoing treatment is genuinely required.